Correction: Diminution of signal transducer and activator of transcription 3 signaling inhibits vascular permeability and anaphylaxis (The Journal of Allergy and Clinical Immunology (2016) 138(1) (187–199) (S0091674916000269) (10.1016/j.jaci.2015.11.024));Diminution of signal transducer and activator of transcription 3 signaling inhibits vascular permeability and anaphylaxis

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 1, 2016, Pages 187-199

  Hox, Valerie ^a   O'Connell, Michael P ^a   Lyons, Jonathan J ^a   Sackstein, Paul ^a   Dimaggio, Thomas ^a   Jones, Nina ^c   Nelson, Celeste ^a   Boehm, Manfred ^b   Holland, Steven M ^a   Freeman, Alexandra F ^a   Tweardy, David J ^d   Olivera, Ana ^a   Metcalfe, Dean D ^a   Milner, Joshua D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Allergy; autosomal dominant hyper IgE syndrome; immunology; innate immunity; signal transducer and activator of transcription 3

Indexed keywords

BETA CATENIN; HISTAMINE RECEPTOR; IMMUNOGLOBULIN E; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; STAT3 PROTEIN; TRANSCRIPTION FACTOR E2F1; VASCULAR ENDOTHELIAL CADHERIN; AUTACOID; CYTOKINE; PROTEIN TYROSINE KINASE;

ADHERENS JUNCTION; ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MAST CELL; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRICK TEST; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYSTEMIC ANAPHYLAXIS; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CAPILLARY PERMEABILITY; DEGRANULATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MUTATION; SKIN TEST;

ADHERENS JUNCTIONS; ANAPHYLAXIS; ANIMALS; BETA CATENIN; CAPILLARY PERMEABILITY; CELL DEGRANULATION; CYTOKINES; DISEASE MODELS, ANIMAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOGLOBULIN E; INFLAMMATION MEDIATORS; MAST CELLS; MICE; MICE, KNOCKOUT; MUTATION; RECEPTORS, HISTAMINE; SIGNAL TRANSDUCTION; SKIN TESTS; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR;

EID: 84961221183     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2017.05.003     Document Type: Erratum

References (52)

1. 1 Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., Akira, S., Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol 161 (1998), 4652–4660.
2. 2 Sano, S., Itami, S., Takeda, K., Tarutani, M., Yamaguchi, Y., Miura, H., et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 18 (1999), 4657–4668.
3. 3 Hirano, T., Ishihara, K., Hibi, M., Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19 (2000), 2548–2556.
4. 4 Casanova, J.L., Holland, S.M., Notarangelo, L.D., Inborn errors of human JAKs and STATs. Immunity 36 (2012), 515–528.
5. 5 Flanagan, S.E., Haapaniemi, E., Russell, M.A., Caswell, R., Lango Allen, H., De Franco, E., et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet 46 (2014), 812–814.
6. 6 Milner, J.D., Vogel, T.P., Forbes, L., Ma, C.A., Stray-Pedersen, A., Niemela, J.E., et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 125 (2015), 591–599.
7. 7 Haapaniemi, E.M., Kaustio, M., Rajala, H.L., van Adrichem, A.J., Kainulainen, L., Glumoff, V., et al. Autoimmunity, hypogammaglobulinemia, lymphoproliferation and mycobacterial disease in patients with dominant activating mutations in STAT3. Blood 125 (2015), 639–648.
8. 8 Freeman, A.F., Holland, S.M., Clinical manifestations of hyper IgE syndromes. Dis Markers 29 (2010), 123–130.
9. 9 Siegel, A.M., Stone, K.D., Cruse, G., Lawrence, M.G., Olivera, A., Jung, M.Y., et al. Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation. J Allergy Clin Immunol 132 (2013), 1388–1396.
10. 10 Erlich, T.H., Yagil, Z., Kay, G., Peretz, A., Migalovich-Sheikhet, H., Tshori, S., et al. Mitochondrial STAT3 plays a major role in IgE-antigen-mediated mast cell exocytosis. J Allergy Clin Immunol 134 (2014), 460–469.
11. 11 Palmer, R.M., Ferrige, A.G., Moncada, S., Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 (1987), 524–526.
12. 12 Mitsuhata, H., Shimizu, R., Yokoyama, M.M., Role of nitric oxide in anaphylactic shock. J Clin Immunol 15 (1995), 277–283.
13. 13 Valone, F.H., Johnson, B., Modulation of platelet-activating-factor-induced calcium influx and intracellular calcium release in platelets by phorbol esters. Biochem J 247 (1987), 669–674.
14. 14 Kotlikoff, M.I., Murray, R.K., Reynolds, E.E., Histamine-induced calcium release and phorbol antagonism in cultured airway smooth muscle cells. Am J Physiol 253 (1987), C561–C566.
15. 15 Kaliner, M., Sigler, R., Summers, R., Shelhamer, J.H., Effects of infused histamine: analysis of the effects of H-1 and H-2 histamine receptor antagonists on cardiovascular and pulmonary responses. J Allergy Clin Immunol 68 (1981), 365–371.
16. 16 Kirsch, C.M., Brokaw, J.J., Prow, D.M., White, G.W., Mechanism of platelet activating factor-induced vascular leakage in the rat trachea. Exp Lung Res 18 (1992), 447–459.
17. 17 Andriopoulou, P., Navarro, P., Zanetti, A., Lampugnani, M.G., Dejana, E., Histamine induces tyrosine phosphorylation of endothelial cell-to-cell adherens junctions. Arterioscler Thromb Vasc Biol 19 (1999), 2286–2297.
18. 18 Wallez, Y., Cand, F., Cruzalegui, F., Wernstedt, C., Souchelnytskyi, S., Vilgrain, I., et al. Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene 26 (2007), 1067–1077.
19. 19 Weis, S., Cui, J., Barnes, L., Cheresh, D., Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 167 (2004), 223–229.
20. 20 Deo, D.D., Bazan, N.G., Hunt, J.D., Activation of platelet-activating factor receptor-coupled G alpha q leads to stimulation of Src and focal adhesion kinase via two separate pathways in human umbilical vein endothelial cells. J Biol Chem 279 (2004), 3497–3508.
21. 21 Geletu, M., Guy, S., Arulanandam, R., Feracci, H., Raptis, L., Engaged for survival: from cadherin ligation to STAT3 activation. JAKSTAT, 2, 2013, e27363.
22. 22 Wei, L.H., Chou, C.H., Chen, M.W., Rose-John, S., Kuo, M.L., Chen, S.U., et al. The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model. J Clin Endocrinol Metab 98 (2013), E472–E484.
23. 23 Guy, S., Geletu, M., Arulanandam, R., Raptis, L., Stat3 and gap junctions in normal and lung cancer cells. Cancers (Basel) 6 (2014), 646–662.
24. 24 Snyder-Talkington, B.N., Schwegler-Berry, D., Castranova, V., Qian, Y., Guo, N.L., Multi-walled carbon nanotubes induce human microvascular endothelial cellular effects in an alveolar-capillary co-culture with small airway epithelial cells. Part Fibre Toxicol, 10, 2013, 35.
25. 25 Dai, B., Meng, J., Peyton, M., Girard, L., Bornmann, W.G., Ji, L., et al. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res 71 (2011), 3658–3668.
26. 26 van Haaften, G., Agami, R., Tumorigenicity of the miR-17-92 cluster distilled. Genes Dev 24 (2010), 1–4.
27. 27 Armanious, H., Gelebart, P., Mackey, J., Ma, Y., Lai, R., STAT3 upregulates the protein expression and transcriptional activity of beta-catenin in breast cancer. Int J Clin Exp Pathol 3 (2010), 654–664.
28. 28 Kawada, M., Seno, H., Uenoyama, Y., Sawabu, T., Kanda, N., Fukui, H., et al. Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of beta-catenin in colorectal cancer. Cancer Res 66 (2006), 2913–2917.
29. 29 Steward-Tharp, S.M., Laurence, A., Kanno, Y., Kotlyar, A., Villarino, A.V., Sciume, G., et al. A mouse model of HIES reveals pro- and anti-inflammatory functions of STAT3. Blood 123 (2014), 2978–2987.
30. 30 Olivera, A., Eisner, C., Kitamura, Y., Dillahunt, S., Allende, L., Tuymetova, G., et al. Sphingosine kinase 1 and sphingosine-1-phosphate receptor 2 are vital to recovery from anaphylactic shock in mice. J Clin Invest 120 (2010), 1429–1440.
31. 31 Kuehn, H.S., Beaven, M.A., Ma, H.T., Kim, M.S., Metcalfe, D.D., Gilfillan, A.M., Synergistic activation of phospholipases Cgamma and Cbeta: a novel mechanism for PI3K-independent enhancement of FcepsilonRI-induced mast cell mediator release. Cell Signal 20 (2008), 625–636.
32. 32 Gavard, J., Gutkind, J.S., VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 8 (2006), 1223–1234.
33. 33 Fukuhara, S., Sakurai, A., Sano, H., Yamagishi, A., Somekawa, S., Takakura, N., et al. Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway. Mol Cell Biol 25 (2005), 136–146.
34. 34 Redell, M.S., Ruiz, M.J., Alonzo, T.A., Gerbing, R.B., Tweardy, D.J., Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117 (2011), 5701–5709.
35. 35 Sidibe, A., Imhof, B.A., VE-cadherin phosphorylation decides: vascular permeability or diapedesis. Nat Immunol 15 (2014), 215–217.
36. 36 Dey, N., Crosswell, H.E., De, P., Parsons, R., Peng, Q., Su, J.D., et al. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res 68 (2008), 1862–1871.
37. 37 McKinley, D., Wu, Q., Yang-Feng, T., Yang, Y.C., Genomic sequence and chromosomal location of human interleukin-11 gene (IL11). Genomics 13 (1992), 814–819.
38. 38 Matsumiya, T., Imaizumi, T., Fujimoto, K., Cui, X., Shibata, T., Tamo, W., et al. Soluble interleukin-6 receptor alpha inhibits the cytokine-Induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture. Exp Cell Res 269 (2001), 35–41.
39. 39 Xie, W., Jin, L., Mei, Y., Wu, M., E2F1 represses beta-catenin/TCF activity by direct up-regulation of Siah1. J Cell Mol Med 13 (2009), 1719–1727.
40. 40 Qin, G., Kishore, R., Dolan, C.M., Silver, M., Wecker, A., Luedemann, C.N., et al. Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF. Proc Natl Acad Sci U S A 103 (2006), 11015–11020.
41. 41 Pal, S., Datta, K., Mukhopadhyay, D., Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 61 (2001), 6952–6957.
42. 42 Kang, N.I., Yoon, H.Y., Kim, H.A., Kim, K.J., Han, M.K., Lee, Y.R., et al. Protein kinase CK2/PTEN pathway plays a key role in platelet-activating factor-mediated murine anaphylactic shock. J Immunol 186 (2011), 6625–6632.
43. 43 Furumoto, Y., Charles, N., Olivera, A., Leung, W.H., Dillahunt, S., Sargent, J.L., et al. PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeability. Blood 118 (2011), 5466–5475.
44. 44 Lee, K.S., Kim, S.R., Park, S.J., Lee, H.K., Park, H.S., Min, K.H., et al. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen-induced airway inflammation. Mol Pharmacol 69 (2006), 1829–1839.
45. 45 Lien, W.H., Fuchs, E., Wnt some lose some: transcriptional governance of stem cells by Wnt/beta-catenin signaling. Genes Dev 28 (2014), 1517–1532.
46. 46 Rosenbluh, J., Wang, X., Hahn, W.C., Genomic insights into WNT/beta-catenin signaling. Trends Pharmacol Sci 35 (2014), 103–109.
47. 47 Clevers, H., Wnt/beta-catenin signaling in development and disease. Cell 127 (2006), 469–480.
48. 48 Menge, T., Gerber, M., Wataha, K., Reid, W., Guha, S., Cox, C.S. Jr., et al. Human mesenchymal stem cells inhibit endothelial proliferation and angiogenesis via cell-cell contact through modulation of the VE-Cadherin/beta-catenin signaling pathway. Stem Cells Dev 22 (2013), 148–157.
49. 49 van Amerongen, R., Fuerer, C., Mizutani, M., Nusse, R., Wnt5a can both activate and repress Wnt/beta-catenin signaling during mouse embryonic development. Dev Biol 369 (2012), 101–114.
50. 50 Nemeth, M.J., Topol, L., Anderson, S.M., Yang, Y., Bodine, D.M., Wnt5a inhibits canonical Wnt signaling in hematopoietic stem cells and enhances repopulation. Proc Natl Acad Sci U S A 104 (2007), 15436–15441.
51. 51 Davis, S.D., Schaller, J., Wedgwood, R.J., Job's Syndrome. Recurrent, “cold”, staphylococcal abscesses. Lancet 1 (1966), 1013–1015.
52. 52 Buckley, R.H., Wray, B.B., Belmaker, E.Z., Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics 49 (1972), 59–70.